[go: up one dir, main page]

MX2012001890A - Sales de lenalidomida. - Google Patents

Sales de lenalidomida.

Info

Publication number
MX2012001890A
MX2012001890A MX2012001890A MX2012001890A MX2012001890A MX 2012001890 A MX2012001890 A MX 2012001890A MX 2012001890 A MX2012001890 A MX 2012001890A MX 2012001890 A MX2012001890 A MX 2012001890A MX 2012001890 A MX2012001890 A MX 2012001890A
Authority
MX
Mexico
Prior art keywords
acid
lenalidomide
sulfonic acid
salts
lenalidomide salts
Prior art date
Application number
MX2012001890A
Other languages
English (en)
Inventor
Jacobus Theodorus Henricus Van Eupen
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of MX2012001890A publication Critical patent/MX2012001890A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a sales de adición de ácido de lenalidomida, en donde el ácido tiene un pKa menor a 1, preferiblemente seleccionado de ácido clorhídrico, ácido bromhídrico, ácido metansulfónico, ácido etansulfónico, ácido bencensulfónico, y ácido p-toluensulfónico, a procesos para su fabricación, y uso en medicina, y a la purificación de la base de lenalidomida.
MX2012001890A 2009-08-12 2009-08-12 Sales de lenalidomida. MX2012001890A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/006857 WO2011018101A1 (en) 2009-08-12 2009-08-12 Lenalidomide salts

Publications (1)

Publication Number Publication Date
MX2012001890A true MX2012001890A (es) 2012-03-26

Family

ID=41328475

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001890A MX2012001890A (es) 2009-08-12 2009-08-12 Sales de lenalidomida.

Country Status (7)

Country Link
US (1) US8686153B2 (es)
EP (1) EP2464638A1 (es)
AU (1) AU2009350978A1 (es)
BR (1) BR112012003138A2 (es)
EA (1) EA201270261A1 (es)
MX (1) MX2012001890A (es)
WO (1) WO2011018101A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
KR20100124710A (ko) * 2008-03-11 2010-11-29 닥터 레디스 레보러터리즈 리미티드 레날리도미드의 제조
US20110060010A1 (en) * 2008-03-13 2011-03-10 Tianjin Hemay Bio-Tech Co., Ltd Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
EP2355802A1 (de) * 2008-11-14 2011-08-17 Ratiopharm GmbH Intermediate und orale darreichungsformen enthaltend lenalidomid
US9808450B2 (en) 2013-03-26 2017-11-07 Celgene Corporation Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
EP3135275B1 (en) 2015-08-27 2020-05-13 Grindeks, A Joint Stock Company Pharmaceutical composition capable of the incorporation of lenalidomide in various crystalline modifications
WO2019092752A2 (en) * 2017-11-13 2019-05-16 Avra Laboratories Pvt. Ltd. Novel salt of lenalidomide and polymorphic forms thereof
EP3505158A1 (en) 2017-12-27 2019-07-03 KRKA, d.d., Novo mesto Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
CN117794909A (zh) * 2021-08-04 2024-03-29 株式会社艾比斯生物 改进物质特性的免疫调节酰胺衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
MX2007002521A (es) * 2004-09-03 2007-05-09 Celgene Corp Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1- oxoisoindolinas sustituidas.
KR20100124710A (ko) 2008-03-11 2010-11-29 닥터 레디스 레보러터리즈 리미티드 레날리도미드의 제조
CN101531653B (zh) * 2008-03-13 2014-07-09 峡江和美药业有限公司 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用

Also Published As

Publication number Publication date
US20120190711A1 (en) 2012-07-26
EA201270261A1 (ru) 2012-07-30
AU2009350978A1 (en) 2012-04-05
US8686153B2 (en) 2014-04-01
BR112012003138A2 (pt) 2016-03-01
WO2011018101A1 (en) 2011-02-17
EP2464638A1 (en) 2012-06-20

Similar Documents

Publication Publication Date Title
MX2012001890A (es) Sales de lenalidomida.
CL2014000659A1 (es) Compuestos derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida, antagonistas del receptor de orexina; composicion farmaceutica; y su uso para la prevencion o el tratamiento de una enfermedad seleccionada del grupo que consiste en trastornos de ansiedad, adiccion, animicos y del apetito.
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
ATE544804T1 (de) Teilaromatisches copolyamid und herstellungsverfahren dafür
EP2382040A4 (en) ADIABATIC REACTOR FOR THE PRODUCTION OF OLEFINES
MX2012006553A (es) Anticuerpos contra csf-1r humano y usos de los mismos.
BRPI1010128A2 (pt) "processo para a fabricação do 2,3,3,3 - tetrafluropropeno"
SG162671A1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
GEP20125407B (en) New process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2h-3- benzazepin-2-one, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
GT201100300A (es) Piperidinas sustituidas
UA97401C2 (ru) Экструдат с улучшенной маскировкой вкуса
MY150014A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
ZA201004467B (en) Triazolopyridazines as pari inhibitors,production thereof,and use as medicaments
DE502007002185D1 (de) Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
MY169295A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
EP2438988A4 (en) CATALYST FOR THE PRODUCTION OF MONOCYCLIC AROMATIC HYDROCARBONS AND METHOD FOR THE PRODUCTION OF MONOCYCLIC AROMATIC HYDROCARBONS
BRPI0910429A2 (pt) mistura para a produção de comprimidos de desintegração rápida
CR20110627A (es) Piperidinas sustituidas
EA200970816A1 (ru) Новая лекарственная форма
PH12017500270A1 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain
MY145611A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
UA96476C2 (ru) Фармацевтические композиции, которые содержат ирбесартан
IL207190A (en) A process for ultra-purification of alginates
UA96574C2 (ru) Использование ивабрадина для получения лекарств, предназначенных для лечения эндотелиальной дисфункции
SE0701694L (sv) Nya bronkdilaterande a,b-omättade amider

Legal Events

Date Code Title Description
FA Abandonment or withdrawal